Galera Therapeutics EBITDA vs. Number Of Shares Shorted

GRTXDelisted Stock  USD 2.58  0.19  6.86%   
Based on Galera Therapeutics' profitability indicators, Galera Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Galera Therapeutics' ability to earn profits and add value for shareholders.
For Galera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Galera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Galera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Galera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Galera Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Galera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Galera Therapeutics Number Of Shares Shorted vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Galera Therapeutics's current stock value. Our valuation model uses many indicators to compare Galera Therapeutics value to that of its competitors to determine the firm's financial worth.
Galera Therapeutics is rated # 4 in ebitda category among its peers. It is rated below average in number of shares shorted category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Galera Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Galera Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Galera Number Of Shares Shorted vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Galera Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(46.69 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Galera Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
2.12 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Galera Number Of Shares Shorted Comparison

Galera Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Galera Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Galera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Galera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Galera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Galera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.

Galera Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Galera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Galera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Galera Therapeutics' important profitability drivers and their relationship over time.

Use Galera Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Galera Therapeutics Pair Trading

Galera Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Galera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galera Therapeutics to buy it.
The correlation of Galera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Galera Therapeutics position

In addition to having Galera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Cap ETFs Thematic Idea Now

Small Cap ETFs
Small Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 168 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Galera Pink Sheet

If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum